Opioid addiction, clinically called opioid use disorder (OUD), is a treatable health condition involving a problematic pattern of opioid use that causes significant impairment or distress.
OUD can involve prescription opioids such as oxycodone or hydrocodone, heroin, fentanyl, or other opioids. Treatment is not limited to residential rehab or detox. Depending on the person's needs, evidence-based care can include medications for opioid use disorder, withdrawal management, outpatient or residential treatment, counseling, mental health care, overdose-prevention planning, and continuing recovery support.
Medication is especially important in opioid treatment. FDA-approved medications for OUD include buprenorphine, methadone, and naltrexone. Treatment with medications is associated with reduced opioid misuse, overdose risk, and death compared with receiving no treatment. U.S. Food and Drug Administration
Opioid addiction is treated using an individualized plan that may combine medication, medical care, behavioral treatment, mental health services, and recovery support.
For many people with OUD, medication is a central part of care rather than an optional add-on. CDC recommends evidence-based medications for opioid use disorder and specifically warns that detoxification by itself, without ongoing MOUD, is not recommended because of increased risks of returning to opioid use, overdose, and overdose death. CDC
Treatment can happen in outpatient healthcare, opioid treatment programs, residential rehab, intensive outpatient programs, primary care, behavioral-health settings, or a combination of services over time.
Opioid use disorder is the medical term commonly used for opioid addiction.
A person with OUD may have difficulty controlling opioid use even when it is causing problems with health, relationships, work, school, finances, safety, or other areas of life.
The condition is diagnosed based on a broader pattern of behavior and symptoms rather than simply whether someone has ever experienced withdrawal.
CDC notes that OUD can involve using more opioids than intended, unsuccessful efforts to reduce use, strong cravings, continued use despite harm, difficulty fulfilling responsibilities, hazardous use, and other signs. Tolerance and withdrawal may also be relevant, although those two criteria are handled differently when opioids are being taken solely under appropriate medical supervision. CDC
This distinction matters because physical dependence is not automatically the same as opioid addiction.
OUD can develop in connection with several types of opioids.
Prescription opioids include medications such as oxycodone, hydrocodone, morphine, and others used in medical care.
Heroin is an illicit opioid.
Fentanyl has legitimate medical uses but is also manufactured illegally. Illegally made fentanyl may be present in counterfeit pills or mixed with other drugs without a person's knowledge.
Read the fentanyl addiction treatment guide →That treatment gap is important because medication is one of the strongest evidence-based tools available for OUD. SAMHSA
The overdose burden also remains substantial. Final CDC data show that 54,045 U.S. overdose deaths in 2024 involved an opioid. Of those, 47,735 involved synthetic opioids other than methadone, a category that includes fentanyl but is not a fentanyl-only count. Opioid overdose mortality declined significantly from 2023 to 2024, but thousands of deaths still occurred. CDC
Someone may benefit from professional assessment when opioid use becomes difficult to control or repeatedly interferes with everyday life.
A person may find that they use opioids longer or in larger amounts than intended, repeatedly try to cut down without success, experience strong cravings, or spend increasing amounts of time obtaining, using, or recovering from opioids.
Work, school, family responsibilities, relationships, health, or safety may also begin to suffer.
Continued opioid use despite recognizing serious physical, psychological, or social consequences can be another sign that professional evaluation is appropriate.
You do not need to diagnose yourself before asking about treatment.
Treatment typically begins with an assessment.
A healthcare or addiction professional may review the opioids being used, recent fentanyl exposure, withdrawal symptoms, overdose history, other substance use, medications, physical health, mental health, previous treatment, living environment, support system, and treatment goals.
The goal is to determine what the person needs now rather than automatically placing everyone into the same program.
Someone may need withdrawal-management services first. Another person may be able to begin medication treatment in an outpatient setting. A person with significant medical, psychiatric, or environmental risks may need more structured care.
When someone has developed physical dependence on opioids, reducing or stopping opioid use can cause withdrawal.
Symptoms can include restlessness, anxiety, sweating, muscle aches, trouble sleeping, stomach discomfort, nausea, vomiting, diarrhea, and strong cravings.
The experience can vary substantially depending on the opioid involved, pattern of use, other substances, medications, health conditions, and individual factors.
A rigid online “Day 1 through Day 7” detox timeline is therefore not appropriate for everyone.
When withdrawal-management services are needed, they may provide symptom monitoring, supportive care, medication, and stabilization.
However, withdrawal management is only one part of treatment.
No.
Detox can help someone through immediate withdrawal and may provide monitoring, supportive care, medication, and stabilization.
After withdrawal, cravings, reduced tolerance, mental health symptoms, unstable living conditions, triggers, and other risks can remain. Continuing care addresses the full opioid use disorder rather than withdrawal alone.
CDC specifically advises against detoxification alone without medication treatment for OUD because it can increase the risk of returning to opioid use, overdose, and overdose death. CDC
This is especially important because opioid tolerance can fall after a period of reduced or no use. Returning to an amount previously tolerated may become much more dangerous.
FDA-approved medications for OUD include buprenorphine, methadone, and naltrexone. All three are evidence-based treatment options. U.S. Food and Drug Administration
Buprenorphine can reduce withdrawal symptoms and cravings.
It can be prescribed in office-based healthcare and other eligible settings. The former federal DATA or “X-waiver” is no longer required for qualified prescribers, although clinicians must still follow applicable federal and state requirements. FDA
Methadone is used to reduce withdrawal and cravings and help stabilize opioid use.
In the United States, methadone used specifically to treat OUD is generally dispensed through a SAMHSA-certified opioid treatment program. Federal OTP rules were substantially updated in 2024 to allow more individualized treatment. SAMHSA
Naltrexone blocks opioid effects rather than activating opioid receptors. Extended-release injectable naltrexone is FDA-approved for OUD.
Because opioids need to be cleared appropriately before naltrexone is started, initiation should be managed by a qualified healthcare professional rather than through a self-directed schedule.
No.
Counseling and behavioral healthcare can be useful, but medication should not automatically be delayed because counseling is unavailable or because a patient declines a particular psychosocial service.
FDA guidance states that OUD medication should include an offer of counseling or other services when possible, but access to medication should not be made contingent on participation in those services. FDA
SAMHSA's updated OTP rules similarly state that medication access is no longer contingent on counseling participation. SAMHSA
The right treatment plan can still include individual counseling, group therapy, family support, peer services, psychiatric care, or other behavioral-health treatment when those services are helpful.
Medication can address important biological aspects of OUD, including withdrawal and cravings.
Therapy can address other areas of recovery.
Someone may work on triggers, stress, relationships, decision-making, trauma, mental health, motivation, daily routines, and strategies for difficult situations.
Treatment may involve individual counseling, group treatment, family services, cognitive and behavioral approaches, motivational strategies, or other services.
The best approach should be individualized rather than requiring every person with OUD to complete the same counseling program.
Opioid use disorder does not automatically require inpatient rehab.
Residential or inpatient treatment may be appropriate when someone needs a highly structured environment, has significant medical or psychiatric needs, lives in an unstable recovery environment, or has other risks that make community-based treatment difficult.
Read the inpatient drug rehab guide →
Outpatient treatment allows someone to live outside the facility while attending scheduled medical, counseling, or recovery services.
Outpatient OUD treatment may include buprenorphine or naltrexone, counseling, psychiatric services, telehealth, and other care depending on the provider.
Read the outpatient drug rehab guide →
Methadone treatment for OUD is generally provided through certified OTPs rather than ordinary outpatient prescribing.
Depression, anxiety, PTSD, bipolar disorder, and other mental health conditions can occur alongside opioid use disorder.
When both are present, treatment may need to address both conditions together.
Mental health symptoms can affect substance use, sleep, safety, treatment participation, medication decisions, and recovery.
A coordinated approach can include addiction medication, psychotherapy, psychiatric care, case management, and other support.
Pregnancy changes how opioid use disorder should be treated.
Current CDC guidance recommends methadone or buprenorphine for pregnant patients with OUD rather than rapidly stopping opioids or routinely using supervised withdrawal as the preferred approach. CDC
Prenatal and addiction-treatment clinicians should coordinate care.
Someone who is pregnant or may be pregnant should not stop OUD medication or attempt opioid withdrawal based solely on information from a website.
Opioid treatment should address overdose risk as well as longer-term recovery.
Naloxone can temporarily reverse an opioid overdose and should be available when opioid exposure is possible.
Even people receiving effective OUD treatment may still face overdose risk if they return to opioid use, use other substances, or experience changes in tolerance.
FDA encourages clinicians treating OUD to discuss naloxone, and treatment programs should include overdose education as part of safety planning. FDA
Naloxone is emergency overdose reversal; it does not replace ongoing OUD treatment.
A return to opioid use can be dangerous, but it does not automatically mean treatment should end.
It may indicate that medication, treatment intensity, mental health care, housing, recovery support, or another part of the treatment plan needs to be reassessed.
Stopping effective medication as punishment for continued or renewed substance use can create additional risk.
Treatment should focus on safety, updated clinical needs, and continued engagement in care.
There is no universal treatment length.
Someone may spend a short period in residential care and then continue outpatient medication and counseling.
Another person may never need residential treatment at all.
Medication for OUD may continue for months, years, or longer when it remains beneficial.
Treatment should not be stopped simply because an arbitrary calendar date has been reached.
The appropriate duration depends on the person's response to treatment, safety, goals, medical needs, recovery environment, and preferences.
A treatment program should be able to explain how it assesses opioid use disorder and how it decides which level of care is appropriate.
For OUD, one of the most important questions is whether the program provides or coordinates evidence-based medication.
How does the program assess opioid use disorder and level of care?
Are buprenorphine, methadone, and naltrexone provided or coordinated when appropriate?
How does the program handle withdrawal and stabilization needs?
Does care include naloxone education and overdose-risk planning?
Can the program address or coordinate co-occurring psychiatric needs?
How are medications, recovery services, and follow-up coordinated after discharge?
That answer can reveal more about the program's clinical model than simply asking whether it offers “opioid rehab.”
Insurance may cover opioid use disorder treatment, but the details depend on the specific plan.
Residential care, outpatient treatment, physician services, OTP services, and psychiatric care may be processed differently under an insurance plan.
Prescription medication benefits, prior authorization, networks, deductibles, copayments, and coinsurance may affect what a person pays.
Marketplace health plans cover mental health and substance use disorder services as essential health benefits, although deductibles, copayments, coinsurance, provider networks, authorization rules, and specific medication benefits can still affect what a person pays. HealthCare.gov
Yes. Opioid use disorder is treatable. Treatment can include medication, behavioral healthcare, medical services, mental health treatment, overdose prevention, and ongoing recovery support.
FDA-approved medications for OUD are buprenorphine, methadone, and naltrexone. FDA
No. Withdrawal management can address immediate withdrawal, but CDC advises against detoxification alone without continuing OUD treatment because of increased return-to-use and overdose risks. CDC
No. OUD can be treated in several settings. The appropriate level of care depends on medical needs, withdrawal, mental health, overdose risk, living environment, and other individual factors.
Buprenorphine-containing medications, including buprenorphine/naloxone products, are FDA-approved treatment options for OUD.
Methadone is an FDA-approved medication for opioid use disorder. When provided through treatment, it is used to reduce withdrawal and cravings and support stabilization.
Yes. Fentanyl-related opioid use disorder can be treated using evidence-based OUD medications. The medication and initiation approach should be selected with a qualified clinician.
No. Counseling can be useful, but medication access should not be denied or delayed solely because counseling is unavailable or declined. FDA
There is no universal duration. Treatment and medication may continue as long as they remain clinically appropriate and beneficial.
Give naloxone if available and call 911 immediately.
You do not need to know whether medication, detox, inpatient rehab, or outpatient treatment is the right starting point before asking about available options.
Treatment can be explored based on opioid use, withdrawal risk, overdose history, physical and mental health, living environment, location, insurance, and other individual circumstances.
This page provides general educational information about opioid use disorder, withdrawal, medications, rehab, and overdose prevention. It is not medical advice, diagnosis, medication guidance, or an individualized treatment recommendation.
Do not start, stop, change, or taper medication based solely on information from this page.
Questions about withdrawal, pregnancy, medications, mental health symptoms, or treatment decisions should be discussed with appropriately qualified healthcare professionals.
If someone is experiencing a mental health, suicide, or substance use crisis, call or text 988.
